ABSTRACT
INTRODUCTION
About 12% of all human cancers are known to be caused by viruses (Hausen, 2009) , thus, the detection of viruses in human cancer tissue has significant clinical implications in oncology. The advent of next-generation sequencing (NGS) technologies using pairedend reads allows for the detection of viruses in human cancer tissue at unprecedented levels of efficiency and precision. Several groups have developed computational tools for pathogen/virus discovery by exploiting the great amount of NGS data obtained from human tissue (Kostic et al., 2011 , Isakov et al., 2011 . These groups have implemented a computational subtraction analysis, which has also been used to discover a new polyomavirus associated with most cases of Merkel cell carcinoma (Feng, et al., 2008) .
Although detecting viruses in human tissue is important in clinical oncology, investigating virus integration sites in host cell chromosomes is equally valuable since insertional mutagenesis is one of the most critical steps in the pathogenesis of hepatitis B virus (HBV)-mediated hepatocellular carcinoma (HCC; PaterliniBrechot, et al., 2003) . NGS data have been used to map the HBV integration sites in HCC samples (Sung et al., 2012 , Jiang et al., 2012 . However, no software tool is currently available for detecting viral integration sites by NGS data. We present VirusSeq, which starts with computational subtraction on NGS data, and subsequently identifies viruses and their potential integration sites in the human genome with high specificity and sensitivity.
METHODS
(1) Mapping/Alignment. The paired-end (PE) reads in FASTQ format are used as input. VirusSeq works with both whole-genome * To whom correspondence should be addressed.
and whole-transcriptome sequencing data. The raw PE reads are aligned to the reference genome using MOSAIK (Hiller et al., 2008 ) alignment software, which implements both a hashing scheme and the Smith-Waterman algorithm to produce gapped optimal alignments.
(2) Virus detection from NGS data: VirusSeq starts with computational subtraction of human sequences by aligning raw PE reads from whole-genome/transcriptome sequencing to the human genome reference. Thus, a set of nonhuman sequences is effectively generated by subtracting the human sequences. In the second step, VirusSeq aligns the nonhuman sequences against a comprehensive database that includes all known viral sequences from Genome Information Broker for Viruses (GIB-V, http://gibv.genes.nig.ac.jp/), and quantifies the virus representation by the overall count of mapped reads within a virus genome to determine the existence of viruses in human samples with an empirical cutoff. Any virus with an overall count of mapped reads below the cutoff is treated as nonexistent. We used 1000 as the cutoff for the overall count of mapped reads within a virus genome; this cutoff should be applicable for both RNA-Seq data and whole-genome sequencing data with 30X coverage. This cutoff should be reduced by half or more for low-pass whole-genome sequencing data.
(3) Identification of virus integration sites:
The genome sequences of viruses, which are well known in terms of cancer association and were detected in the previous step in our TCGA dataset, were concatenated into a single chromosome named chrVirus, with related annotation of each viral gene in refFlat format. A new hybrid reference genome named hg19Virus is built by combining hg19 and chrVirus (designated as chr25 in hg19Virus). All PE reads without computational subtraction are mapped to this reference (hg19Virus). If the PE reads are uniquely mapped with one end to one human chromosome and the other to chr25, the read pair is reported as a discordant read pair. All discordant reads are then annotated with human and viral genes defined in the curated refFlat file. VirusSeq then clusters the discordant read pairs that support the same integration (fusion) event (e.g., HBV-MLL4). VirusSeq implements a dynamic clustering procedure (details in Supplementary Notes) to accurately determine the boundary of the cluster, whose size is constrained by the insert size (fragment length) distribution. In order to remove outliers within a cluster, VirusSeq implements the robust "extreme studentized deviate (ESD)" multiple-outlier detection procedure (Rosner, 1983) . Once outliers are detected within a cluster, the cluster boundary is reset by excluding the outlier reads. VirusSeq reports the fusion candidates by using both supporting pairs (at least four) and junction spanning reads (at least one) as the cutoffs. Meanwhile, an in silico sequence is generated using the consensus of reads within discord-ant read clusters for each fusion candidate to help the PCR primer design, which facilitates quick PCR validation.
RESULTS AND DISCUSSION
To test the accuracy of VirusSeq, we analyzed RNA-Seq data of 17 HCC cancers available in the TCGA database and detected HBV transcripts in 4 cases (Table 1A) , two of which are from patients with serologic evidence of HBV infection and one from a patient who is seronegative for HBV (and hepatitis C virus). Serology data were not available for the remaining case. Viral integration loci identified in our analysis included known genes MLL4 (2 cancers; both from the two HBV-seropositive patients) and TERT, ITGAD, TEAD1, TECRL, C19orf55, and MIR548D2. Interestingly, the cancer with TERT-associated HBV sequences came from the patient who was reportedly seronegative for HBV. Our findings validate other reports that have demonstrated HBV insertion in TERT and MLL4 (Ferber et al., 2003 , Saigo et al., 2008 . We also analyzed RNA-Seq data of 239 cases of head and neck squamous cell carcinoma (HNSCC) available in the TCGA database. We detected human papillomavirus (HPV) transcripts in 37 cancers, as follows: 30 cancers with HPV16, 5 cancers with HPV33, 1 cancer with HPV35, and 1 cancer with Epstein-Barr virus (EBV). In 24 cancers, HPV transcripts encoding for key viral proteins/oncoproteins (E7 in 22 cases; E6 in 20 cases; E1 in 17 cases and E4 in 8 cases) were integrated in the cancer genome, the majority in association with known genes. We used the HPV16 status from colorimetric in situ hybridization and the p16 immunohistochemistry data (clinical data) to estimate the sensitivity and specificity for HPV16 detection. We found that a total of 8 samples were HPV16-positive from colorimetric in situ hybridization (6 HPV16-positive) and/or p16 immunohistochemistry (7 HPV16-positive), and 36 samples were HPV16-negative. The HPV16 status was not available for all the remaining samples. The confidence intervals (CIs) were estimated using the Wilson score method by taking the sample size into consideration. For this HNSCC dataset, the sensitivity was 100% (8/8) with a 95% CI of 67.6% to 100%, and specificity was 100% (36/36) with a 95% CI of 90.4% to 100% (Table 1B) .
We have developed a new algorithmic method called VirusSeq for detecting the known viruses and their integration sites in the human genome using NGS data. We evaluated VirusSeq on RNASeq data of 17 HCC and 239 HNSCC samples, and showed that VirusSeq accurately detects the known viruses and their integration sites. VirusSeq can also perform this function using whole-genome sequencing data obtained from human tissue. The main limitation of VirusSeq is the requirement of the known virus database to nominate candidate viruses in human cancer tissue. This will certainly miss novel viruses that are not in the virus database. We expect VirusSeq to be an effective solution for detecting viruses and their integration sites in cancer studies. We invite users to test our software.
